Merck and Revolution Medicines Talks May Restart
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: stocktwits
- Stock Fluctuations: Since January 7, Revolution Medicines' stock has gained nearly 15% following reports of AbbVie's interest, but shares fell nearly 20% in overnight trading after Merck shelved acquisition talks due to price disagreements.
- Acquisition Negotiation Dynamics: Although talks between Merck and Revolution have stalled, Wall Street analysts expect investors to buy the dip, viewing it as a buying opportunity, particularly with a catalyst-rich outlook for 2026.
- Market Reaction: Retail sentiment on Revolution Medicines has shifted to 'bullish', with message volumes on Stocktwits surging 666% in the past 24 hours, indicating a significant increase in market interest.
- Drug Development Prospects: Revolution's experimental drug daraxonrasib has received a fast-track review voucher from the FDA and is in late-stage trials, targeting multiple mutations in RAS genes, which could impact major cancers like lung and pancreatic cancer.
Analyst Views on RVMD
Wall Street analysts forecast RVMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVMD is 86.00 USD with a low forecast of 67.00 USD and a high forecast of 147.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
20 Buy
0 Hold
0 Sell
Strong Buy
Current: 118.810
Low
67.00
Averages
86.00
High
147.00
Current: 118.810
Low
67.00
Averages
86.00
High
147.00
About RVMD
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
